- Home
- MUA vs ADCT Comparison
MUA vs ADCT Comparison
Compare MUA & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUA
- ADCT
- Stock Information
- Founded
- MUA 1993
- ADCT 2011
- Country
- MUA United States
- ADCT Switzerland
- Employees
- MUA N/A
- ADCT N/A
- Industry
- MUA Investment Bankers/Brokers/Service
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- MUA Finance
- ADCT Health Care
- Exchange
- MUA Nasdaq
- ADCT Nasdaq
- Market Cap
- MUA 427.1M
- ADCT 380.2M
- IPO Year
- MUA N/A
- ADCT 2020
- Fundamental
- Price
- MUA $10.74
- ADCT $4.63
- Analyst Decision
- MUA
- ADCT Strong Buy
- Analyst Count
- MUA 0
- ADCT 6
- Target Price
- MUA N/A
- ADCT $7.80
- AVG Volume (30 Days)
- MUA 92.6K
- ADCT 1.2M
- Earning Date
- MUA 01-01-0001
- ADCT 11-06-2025
- Dividend Yield
- MUA 4.84%
- ADCT N/A
- EPS Growth
- MUA N/A
- ADCT N/A
- EPS
- MUA N/A
- ADCT N/A
- Revenue
- MUA N/A
- ADCT $77,246,000.00
- Revenue This Year
- MUA N/A
- ADCT $13.47
- Revenue Next Year
- MUA N/A
- ADCT $5.88
- P/E Ratio
- MUA N/A
- ADCT N/A
- Revenue Growth
- MUA N/A
- ADCT 15.73
- 52 Week Low
- MUA $8.61
- ADCT $1.05
- 52 Week High
- MUA $11.43
- ADCT $4.74
- Technical
- Relative Strength Index (RSI)
- MUA 40.49
- ADCT 71.32
- Support Level
- MUA $10.51
- ADCT $4.15
- Resistance Level
- MUA $11.14
- ADCT $4.74
- Average True Range (ATR)
- MUA 0.19
- ADCT 0.28
- MACD
- MUA -0.08
- ADCT 0.06
- Stochastic Oscillator
- MUA 24.74
- ADCT 89.45
About MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations. The Fund invests more of its total assets in municipal bonds.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).